ADDvise completes a directed share issue of 8.0 million SEK

01-02-2016   Non-regulatory press release

The reason for deviation from the shareholders preferential rights and the motives for the share issue is to finance the acquisition of LabRum AB and broaden the shareholder base with qualified investors. The issue increases the number of shares of series B in the Company by 3,791,469 shares. The company's total number of outstanding shares increases from 22,468,178 shares to a total of 26,259,647 shares, divided into 7,619,439 class A shares and 18,640,208 B shares. The directed share issue will increase the share capital by 3,791,469 SEK, from 22,468,178 to 26,259,647 SEK and increases the number of voting rights from 9,104,313 to 9,483,460 votes. The acquisition: On December 7th, 2015 ADDvise signed a letter of intent to acquire LabRum AB. The Buyer's due diligence is expected to be completed, the share purchase agreement signed and the acquisition completed in early 2016. Financial advisor: Mangold Fondkommission AB is financial advisor to ADDvise in connection with the issue.

For further information, please contact:

Rikard Akhtarzand, CEO, +46 765-25 90 71

About ADDvise Group AB

ADDvise Group AB (publ) is an expansive group which through its subsidiaries IM-Medico Svenska AB, KEBO Inredningar Sverige AB, ADDvise Tillquist AB, Sonesta Medical AB, Sonesta Medical Inc and Surgical Tables Inc offers comprehensive solutions in the form of products and services to healthcare and research facilities. ADDvise Group's customers are located in both the private and public sectors. The Company's share is listed on First North Premier and Mangold Fondkommission AB, +46 8-503015 50, is the company's Certified Adviser and liquidity provider.

Latest press releases

ADDvise Group’s nomination committee for the Annual General Meeting 2022


In accordance with the resolution at the 2021 annual general meeting of ADDvise Group AB, the nomination committee for the annual general meeting 2022 shall be composed of representatives of the three largest shareholders by votes listed in the shareholders’ register, which is maintained by Euroclear Sweden as of 30 June 2021, and the chairman…

ADDvise Group’s reporting dates 2022


Year-End Report 2021 (Jan-Dec)                                 2022-02-24 Last day for shareholders to request                            2022-03-18 an item to be included to the agenda of the Annual General Meeting Interim Report (Jan-March 2022)                       …

On account of the difference in price movements in ADDvise Group’s shares


ADDvise Group AB (publ) (“ADDvise” and the “Company”) notes positive price movements in the Company's shares. ADDvise's share of series A carries one vote and share of series B carries one tenth of a vote, and besides this difference, the Company is not aware of any information concerning the Company which explains the difference between…

ADDvise updates long-term financial goals


ADDvise Group AB raises its long-term EBITDA financial target from 15% to 20%. ADDvise also raises its long-term revenue growth target from 20% to 25%. Other long-term financial goals remain unchanged. For the financial year 2022, on a pro forma basis rolling 12 months, ADDvise expects to reach revenue of SEK 1 billion with an…